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Background: In patients with COPD, the 6-minute walk test (6MWT) and the 30-second sit-
to-stand test (30sec-STS) are widely used as clinical outcome measures of walking capacity, 
lower limb muscle strength, and functional ability. Due to a documented learning effect, at 
least two trials are recommended for assessment. The aim of our study was to investigate the 
intra- and inter-rater reliability and agreement of the two tests in patients with severe and very 
severe COPD (FEV
1
 ,50%).
Patients and methods: Fifty patients (22 females; mean [SD]: age 67 [9] years, FEV
1
 pre-
dicted 32 [9]%) were assessed with the 6MWT and the 30sec-STS twice by the same assessor 
on test-day 1 (T1) and by another assessor 7–10 days later on test-day 2 (T2).
Results: The 6MWT intra- and inter-rater reliability (intraclass correlation coefficient, ICC
1.1
) 
was 0.98 (lower limit 95% CI: 0.94) and 0.96 (lower limit 95% CI: 0.94), respectively, and 
agreement (standard error of the measurement, SEM) was 14.8 and 20.5 m, respectively. The 
30sec-STS intra- and inter-rater reliability and agreement results were, respectively, ICC
1.1
 0.94 
(lower limit 95% CI: 0.90) and 0.92 (lower limit 95% CI: 0.86), with SEM of 0.97 and 1.14 
repetitions. There was no difference (95% CI: -5.3; 8.1) between the 6MWT distances on T1, 
while the mean walking distance improved 7.9 m (0.0 m; 15.8 m) from T1 to T2. Improvement 
on the same test date was less likely (OR: 3.6 [95% CI: 1.1; 11.8], Fisher’s exact test, P=0.047) 
in patients who walked less than 350 m in the 6MWT. We found no clinically relevant learning 
effect in the 30sec-STS.
Conclusion: In patients with severe and very severe COPD the 6MWT and the 30sec-STS 
showed excellent intra- and inter-rater reliability and acceptable agreement. No learning effect 
was documented for the tests when performed on the same day. Our data suggest that in clinical 
practice using different assessors is acceptable, and that a single test trial may be sufficient to 
assess patients with severe and very severe COPD.
Keywords: COPD, exercise test, outcome assessment, lower extremity, reproducibility of 
results
Background
Pulmonary rehabilitation is a key standard treatment of COPD in order to reduce 
COPD symptoms and improve functional ability and quality of life.1–3 Functional 
performance tests designed to assess changes in the ability to perform specific tasks 
of daily activities should in particular be considered when evaluating pulmonary 
rehabilitation.4,5 Feasible and reproducible tests for assessing functional ability are 
needed. Reproducibility parameters are population-specific and can be distinguished 
in reliability parameters that assess whether patients can be discriminated from each 
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other despite measurement errors, and agreement parameters 
that assess how close the results of repeated measures are by 
estimation of the error in repeated measurements.6,7 Agree-
ment parameters are preferable when the test is used for 
evaluating changes over time.6–8
The 6-minute walk test (6MWT) is recommended as 
one of the two gold-standard field tests to assess functional 
walking capacity and to evaluate treatment response from 
COPD rehabilitation programs.9,10 The ability to get up from 
a seated position is crucial to a number of everyday activities 
necessary for autonomy; and in older persons the sit-to-stand 
(STS) tests are commonly used to measure lower extremity 
function.4,5,11–16 Different STS tests are used in the evaluation 
of pulmonary rehabilitation including the time to perform 
five repetitions of STS (5STS), and the number of chair rises 
performed in 30 seconds, 60 seconds, or 3 minutes.11,12 Most 
studies on patients with COPD have used the 60-second sit-
to-stand test as a proxy for the 6MWT and as an indicator of 
functional capacity.12,14 Fewer studies have used the shorter 
tests, for example, the 30sec-STS and the 5STS.12 5STS has 
a documented floor effect of 21% in elderly people from 
the general population and 15% in a cohort of patients with 
COPD.13,16 While the 5STS has demonstrated high reliability, 
no reproducibility studies have been performed for the 
30sec-STS.11 The 30sec-STS has been shown to be a valid 
proxy measure for assessing lower limb muscle strength and 
function in patients with COPD.15,17 Furthermore, several 
national health authorities recommend the 30sec-STS as 
a part of a generic screening tool for functional limitation, 
decline, and frailty in the elderly and persons with medical 
conditions.18–20
Numerous studies have reported the intra-rater repro-
ducibility for 6MWT in groups with varying severity of 
COPD.9,21–28 The Guidelines for Reporting Reliability and 
Agreement Studies (GRRAS) emphasize that inter-rater 
reproducibility is of high clinical relevance for multicenter 
studies and daily clinical practice because patients are often 
assessed by different assessors.6,7 Yet, studies reporting the 
inter-rater reproducibility for 6MWT in patients with COPD 
are limited to one study28 while no study has investigated 
the intra- and inter-rater reproducibility for 30sec-STS in 
patients with COPD.11,12
Results from studies on various patient groups show that 
patients typically perform better if the 6MWT and 30sec-STS 
are repeated, indicating that there is a systematic bias, com-
monly due to a learning effect.29–34 Because learning effect 
has been an issue of concern in patients with COPD, the 
recommendation is to use a standardized instruction and to 
use the highest recorded value from at least two test trials for 
the 6MWT with a minimum of 30 minutes rest in between test 
trials.9,10 This recommendation is primarily based on studies 
on heterogeneous groups of patients with varying severity of 
COPD (stage II–IV/moderate to very severe). Since physical 
capacity, activity of daily living, disease symptoms, and 
comorbidities differ substantially from mild to very severe 
COPD, this could influence test variability. Whether a learn-
ing effect is present in a homogenous group of patients with 
severe COPD is unknown. It could be hypothesized that if 
patients with very little or no reserve capacity perform two 
strenuous tests with a 30-minute pause between the trials a 
potential learning effect may be counteracted by fatigue or 
exhaustion.
The primary aim of this study was to investigate the intra- 
and inter-rater reliability and agreement of the 6MWT and 
30sec-STS in patients with severe and very severe COPD 
(stage III–IV). Secondly, we intended to explore possible 
learning effects and other factors associated with repeated 
assessments.
Materials and methods
study design
This intra- and inter-rater reproducibility study was 
part of a randomized controlled multicenter trial (RCT) 
(ClinicalTrials.gov identifier: NCT02667171) investigating 
the effect of online COPD rehabilitation in patients with 
severe and very severe (stage III–IV) COPD.35 We followed 
the GRRAS.7
Participants
Eligible patients for the RCT were identified and recruited 
by respiratory nurses during outpatient COPD control visits 
from University Hospitals Amager, Hvidovre, Bispebjerg, 
Frederiksberg, Herlev, Gentofte, Frederikssund, and Hillerød. 
All patients provided written informed consent. The study 
was approved by the Ethics Committee of the Capital Region 
of Denmark (H-15019380) and the Danish Data Protection 
Agency approved the research database (j.nr.:2012-58-0004). 
All patients who agreed to participate in the RCT were con-
secutively asked to participate in the intra- and inter-rater 
reproducibility study that required an extra assessment visit 
prior to randomization and intervention. Recruitment for 
the reproducibility study commenced on March 18, 2016 
and continued until 50 patients were recruited in March 20, 
2017 (Figure S1 – flowchart). The sample size of 50 patients 
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was chosen based on the recommendation from COnsensus-
based Standards for the selection of health Measurement 
INstruments.8,36
Inclusion criteria were35 adults with a clinical diagnosis 
of COPD defined as the ratio of FEV
1
 to FVC ,0.70 and 
no history of asthma, and a FEV
1
 ,50% corresponding to 
severe or very severe airflow limitation; symptoms equivalent 
to the Medical Research Council dyspnea scale from 2 to 5; 
no participation in pulmonary rehabilitation within the last 
6 months before start of the intervention; and medically 
cleared to participate in a COPD rehabilitation program. 
Inclusion and exclusion criteria corresponded with the cri-
teria in routine COPD rehabilitation in the Capital Region 
of Copenhagen, Denmark.35
study setting and raters
The assessments were conducted at the Respiratory and 
Physical Therapy Departments of five different University 
Hospitals (Hvidovre, Bispebjerg, Herlev, Gentofte, and 
Frederikssund) in Greater Copenhagen. All 10 raters under-
went a 4-hour assessor course to ensure that they followed 
the same assessment protocol, and that testing procedures 
and the recording of results were standardized. In addi-
tion, the raters were required to pass four approved tests to 
obtain accreditation as blinded rater. All raters were familiar 
with the 6MWT and 30sec-STS from clinical practice. The 
median years of experience after graduation as therapist 
was 11.5 years (,10 years [n=3]; 10–20 years [n=4]; and 
.20 years [n=3]). The therapists worked in disease areas 
of geriatrics, cancer, intensive care unit, heart and lung, 
neurology, and orthopedics. The assessments on test-day 1 
(T1) were conducted by one rater. Another rater carried out 
the assessments on the second test-day (T2) and this rater 
was blinded from the results from T1. Finally, the patients 
were instructed not to talk about testing on T1.
Test procedures
Patients were instructed not to do any vigorous activities 
3 hours prior to testing and to take their prescribed medication 
as usual. All assessments on T1 and T2 followed the same 
procedures (Figure 1) and were conducted under the same 
conditions including the same location and time frame from 
10 am to 2 pm, Monday to Friday, with a 7–10 day interval 
from T1 to T2. The test protocol was chosen to simulate 
conditions in everyday clinical practice, where several per-
formance tests and questionnaires are conducted within a 
narrow time frame. If a patient used a walking aid in daily 
life (eg, a rollator or a crutch), he/she was allowed to use 
that aid during the 6MWT at T1 and T2. Patients who used 
portable oxygen carried it themselves in a shoulder bag or 
on a rollator, and oxygen consumption (L/min) was noted 
in the case report form.
6MWT
On each test-day (T1 and T2), two 6MWTs were performed 
(Figure 1) in accordance with standardized guidelines:10 the 
Figure 1 assessment procedures at day 1 (T1) and day 2 (T2 reassessment).
Abbreviations: Dyspnea, perceived dyspnea; end-, measure taken immediately after test completion; 6MWT, six-minute walk test; 30sec-sTs, 30-second sit-to-stand test; 
spO2, arterial oxygen saturation as measured by pulse oximetry.
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walking course was 20 m due to walking space shortage at 
some hospitals and to ensure the same standardized walking 
course at all five locations.10,22 Patients were instructed to 
walk as far as possible in 6 minutes; they received the recom-
mended standardized encouragement; and a 30-minute seated 
rest was mandatory between the first and second 6MWT on 
both test-days (Figure 1). Heart rate (HR), arterial oxygen 
saturation measured by pulse oximetry (SpO
2
), and perceived 
dyspnea (Borg cr-10) were assessed before and after each 
6MWT trial. Oxygen supplementation was used if required 
and prescribed by a chest physician.
30sec-sTs
On each test-day (T1 and T2), two 30sec-STS were per-
formed in accordance with existing protocols (Figure 1).15,37 
The same chair with a seat height of 45–47 cm was used 
throughout all tests, and the patients were asked to stand up 
fully and sit down as many times as possible in 30 seconds 
with arms across the chest starting from the seated position. 
The number of full stands was recorded. Score zero was 
recorded if the patient was unable to rise from the chair 
without using the arms. A 30-minute pause between the first 
and second trial was mandatory in this study.
Other variables
Demographic and descriptive variables such as age, gender, 
height, weight, body mass index, marital status, educa-
tion, smoking status, years with COPD, GOLD, A/B/C/D 
stratification,38 Charlson morbidity index, body mass index, 
airflow obstruction, dyspnea, and exercise capacity (BODE 
index), and lung medications were registered on T1. A chest 
physician or a respiratory nurse performed the lung spirom-
etry test at the Respiratory Department at the referral hospital 
prior to study referral. All hospitals used clinically approved 
spirometry equipment, but manufacture trademark varied 
between hospitals in the Capital Region. The spirometry 
procedure followed the guideline from the Danish Society 
of Respiratory Medicine.39
statistical analysis
Descriptive data are presented as means with SD for continu-
ous data and as medians with range for ordinal data and data 
not normally distributed. Data distribution was inspected by 
histogram and Q–Q plots and verified by Shapiro–Wilk test 
to determine an approximately normal distribution. Paired 
t-test and Wilcoxon signed rank test were used to compare 
systematic bias between two assessments conducted on the 
same day and unpaired t-test and Mann–Whitney U-test were 
used to compare differences between the two raters. Fisher’s 
exact test was used for analyses of categorical data. Intraclass 
correlation coefficient (ICC) was calculated to describe the 
reliability. The ICC
1.1
 model was used because the assess-
ments were conducted at five centers, and all raters did not 
assess each patient.6,40 The ICC for inter-rater reliability was 
calculated from the highest value/best performance registered 
on test-day 1 (T1) and test-day 2 (T2) as recommended in the 
standard recommendation procedure.9,10 The ICC
1.1
 is a fixed 
model addressing both systematic and random error. ICCs 
values between 0 and 0.5 were considered weak, $0.5–0.75 
moderate, $0.75–0.9 good, and $0.9 to have excellent 
reliability. Agreement was calculated as standard error of 
measurement (SEM) using the equation SD*√1-ICC to 
establish the typical error in a single measurement of repeated 
measurements.6,40 The corresponding smallest real difference 
(SRD95%) was calculated by the equation 1.96×√2× SEM 
to express the variation with 95% certainty for individual 
subjects which represents the smallest change to be detected 
beyond the measurement error.40–42 SEM and SRD95% are 
presented in actual units, and expressed as a percentage of 
the mean of the two test sessions (grand mean), making 
comparisons between tests and other studies easier. Bland–
Altman plots were used to visualize potential systematic 
bias around the zero line as well as heteroscedasticity. Iden-
tification of the mean difference with 95% CI and limits of 
agreement (95% LOA) were included in the plots.6,43 The 
significance level was set as P,0.05 for all analyses. Data 
were analyzed using SPSS version 20.0 (IBM Corporation, 
Armonk, NY, USA).
Results
Participants vs non participants
Fifty of the 108 eligible patients agreed to participate in the 
intra- and inter-rater reproducibility study. Twenty-three 
declined participation due to the extra testing date while 
35 patients could not be included because they performed 
the baseline assessment in an RCT ,1 week before the 
scheduled randomization and intervention. The 58 patients 
who did not participate in the reproducibility study did not 
differ significantly from the included patients on baseline 
characteristics (Table 1).
Intra-rater reproducibility
The reliability and agreement of the tests are presented in 
Table 2. Intra-rater reliability for the 6-minute walk distance 
(6MWD) and 30sec-STS were 0.98 (ICC
1.1
) and 0.94 (ICC
1.1
), 
respectively. Agreement was 14.8 m (SEM) for the 6MWD 
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and 0.97 repetitions (SEM) for the 30sec-STS. There was 
no systematic bias between the first and second test trial 
in the 6MWD and 30sec-STS, while a significant increase 
(P,0.05) was found in end HR and self-perceived dyspnea 
from the first to second 6MWT trial. Oxygen saturation was 
similar in both 6MWT trials (Table 2). Three patients were 
unable to rise from the chair at both trials and got score zero. 
Bland–Altman plots with 95% LOA for both tests are shown 
in Figure 2A and B.
Inter-rater reproducibility
The inter-rater reliability and agreement for the 6MWD and 
30sec-STS are presented in Table 3. Inter-rater reliability 
ICC
1.1
 for the 6MWD and 30sec-STS were 0.96 and 0.92, 
respectively. Agreement was 20.5 m (SEM) for the 6MWD 
and 1.14 repetitions (SEM) for the 30sec-STS. There were 
significant improvements in the best test results on T2 com-
pared with T1. The mean differences were 7.9 m (95% CI: 
0.03; 15.8, P=0.049) for the 6MWD and 0.6 repetitions (95% 
CI: 0.2; 1.1, P,0.01) for the 30sec-STS. End HR increased 
by 5.3 beats per minute (95% CI: 2.2; 8.4, P=0.001), while 
saturation and perceived dyspnea remained unchanged 
(Table 3). Three patients were unable to rise from the chair 
on both T1 and T2. Bland–Altman plots with 95% LOA for 
the 6MWD and 30sec-STS are shown in Figure 2C and D.
explorative results from the 6MWT
Results from T1 showed that 56% of the patients 
walked ,350 m (the predefined threshold cut off from the 
BODE index)44 in the first test trial (Table 4). Improve-
ments from the first to the second trial occurred in 73% of 
those who walked $350 m in the first trial and in 43% of those 
who walked ,350 m (Table 4). The proportion difference 
was statistically significant (OR: 3.6 [95% CI: 1.1; 11.8], 
Fisher’s exact test, P=0.047). However, when comparing 
the best results on T1 and T2, the proportion difference was 
no longer present (OR: 1.4 [95% CI: 0.4; 4.2], Fisher’s exact 
test, P=0.772).
explorative results from the 30sec-sTs
Results from T1 showed that 30% of the patients demon-
strated a poor 30sec-STS performance based on a criterion 
referenced score, that is, #8 chair rises, which is associ-
ated with a risk for loss of functional mobility in all age 
groups18,19,45 (Table 5). Improvements from the first to the 
second trial occurred in 27% of those who did #8 chair rises 
and in 23% who did .8 chair rises (Table 5). The proportion 
difference was not statistically significant (OR: 1.2 [95% 
CI: 0.3; 4.9], Fisher’s exact test, P=1.0), and there was no 
difference when comparing the best 30sec-STS results on 
T1 and T2 (OR: 1.4 [95% CI: 0.4; 5.2], Fisher’s exact test, 
P=0.752).
Table 1 Characteristics
Variables Patients 
with COPD
Not 
included
sex, men/women (n) 28/22 21/37
age, years (sD) 66.6±9.0 69.4±9.1
Body mass index, kg/m2, mean (sD) 25.4±5.6 25.8±5.6
FeV1 % predicted, mean (sD) 32.3±9.0 35.1±9.4
FeV1/FVC, mean (sD) 41.4±10.6 45.1±11.8
gOlD I/II/III/IV, % 0/0/54/46 0/0/67/33
a/B/C/D,36 % 0/36/0/64 3/33/7/57
MrC dyspnea scale, median (range) 3.5 (3–5) 3.0 (2–5)
CaT symptoms, mean (sD) 20.8±6.1 18.7±7.6
BODe index points, median (range) 5 (3–9) 5 (3–8)
Charlson index 1/2/$3, % 52/30/18 28/47/26
lTOT, n (%) 4 (8) 9 (16)
Walking aid, stick/walker, n (%) 1/8 (18) 4/17 (36)
highest 6MWD (sD) 347 (102) 330 (103)
highest 30sec-sTs (sD) 10.8 (4.1) 9.8 (4.8)
Notes: Data are presented as mean ± sD, median (range), or percentage in 
non-normally distributed variables. 
Abbreviations: A/B/C/D, risk stratification; BODE index, body mass index, airflow 
obstruction, dyspnea, and exercise capacity; CaT, COPD assessment test; lTOT, 
long-term oxygen therapy; MrC, Medical research Council; 6MWD, six-minute 
walk distance; 30sec-sTs, 30 second sit-to-stand test.
Table 2 Intra-rater reproducibility test-day 1 (T1)
Variables Test one Test two Difference ICC1.1 (LL95) SEM (SEM%) SRD95% (SRD%)
6MWD 329.5±100.9 330.9±109.8 1.4 [-5.3; 8.1] 0.98 (0.96) 14.84 (5) 41.13 (13)
end spO2 90.6±7.9 90.6±7.9 0.0 [-1.1; 1.1] 0.87 (0.78) 2.82 (3) 7.82 (7)
end hr 104.0±19.6 106.5±18.9 2.5 [0.4; 4.7]* 0.91 (0.85) 5.75 (5) 15.94 (15)
end dyspnea 5.7±2.7 6.5±2.6 0.8 [0.5; 1.1]* 0.88 (0.81) 0.93 (15) 2.58 (42)
30sec-sTs 9.9±3.9 9.7±4.1 -0.2 [-0.5; 0.3] 0.94 (0.90) 0.97 (10) 2.68 (27)
Notes: Test one and two and difference are presented as mean ± SD or delta difference [SE 95% CI]. Significant difference between tests is denoted as *P,0.05.
Abbreviations: Dyspnea, perceived dyspnea (Borg cr-10); hr, heart rate (beats per minute); ICC1.1, intraclass correlation coefficient model 1.1; LL 95, lower 95% confidence 
limit; 6MWD, six-minute walk distance (meters); seM, standard error of measurement; seM%, standard error of measurement expressed as a percentage of the mean; 30sec-
sTs, 30 second sit-to-stand test (repetitions); spO2, arterial oxygen saturation as measured by pulse oximetry (%); SRD95%, smallest real difference at the 95% confidence 
level; srD%, smallest real difference as a percentage of the mean.
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Table 3 Inter-rater reproducibility (highest value T1 vs highest value T2)
Variables Rater T1 Rater T2 Difference ICC1.1 (LL95) SEM (SEM%) SRD95% (SRD%)
6MWD 339.3±103.7 347.2±101.7 7.9 [0.02; 15.8]* 0.96 (0.94) 20.46 (6) 56.70 (16)
end spO2 90.6±8.1 89.8±7.6 -0.8 [-0.3; 2.0] 0.86 (0.77) 2.94 (3) 8.15 (9)
end hr 105.4±19.1 110.7±17.7 5.3 [2.2; 8.4]* 0.79 (0.66) 8.48 (8) 23.50 (22)
end dyspnea 6.2±2.6 6.4±2.7 0.2 [-0.1; 0.6] 0.85 (0.75) 1.01 (16) 2.80 (45)
30sec-sTs 10.2±3.9 10.8±4.1 0.6 [0.2; 1.1]* 0.92 (0.86) 1.14 (11) 3.15 (30)
Notes: rater T1, T2, and difference are presented as mean ± SD or delta difference [SE 95% CI]. Significant difference between raters is denoted *P,0.05.
Abbreviations: Dyspnea, perceived dyspnea (Borg cr-10); hr, heart rate (beats per minute); ICC1.1, intraclass correlation coefficient model 1.1; LL 95, lower 95% confidence 
limit; 6MWD, six-minute walk distance (meters); 30sec-sTs, 30 second sit-to-stand test (repetitions); seM, standard error of measurement; seM%, standard error of 
measurement expressed as a percentage of the mean; spO2, arterial oxygen saturation as measured by pulse oximetry (%); srD95%, smallest real difference at the 95% 
confidence level; SRD%, smallest real difference as a percentage of the mean.
Figure 2 Bland–altman plots of the 6MWD and 30sec-sTs.
Notes: Mean difference between tests/or raters (dotted line) with limits of agreement 95% CI (black lines). The dashed line is the regression of change against the mean 
value. (A) 6MWD scores against 6MWD difference from a single rater at test-day 1 (T1). (B) 30sec-sTs scores against 30sec-sTs difference from a single rater at test-day 
1 (T1). (C) 6MWD score difference obtained by two different raters on two separate test-days (T2 vs T1). (D) 30sec-sTs score difference obtained by two different raters 
on two separate test-days (T2 vs T1).
Abbreviations: 30sec-sTs, 30-second sit-to-stand test; 6MWD, 6-minute walk distance.
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Discussion
To the best of our knowledge, this is the first study to investi-
gate the intra- and inter-rater reproducibility of the 30sec-STS 
in patients with COPD. Also, this is only the second study to 
present inter-rater reproducibility of the 6MWT in patients 
with COPD. We found excellent intra- and inter-rater reli-
ability for both tests and acceptable agreement indicating 
that both tests can be used for evaluative purpose even if 
measured by different raters.
6MWT
Based on our findings, the 6MWT appears to be highly reli-
able in patients with severe and very severe COPD. ICC for 
intra-rater reliability was excellent and consistent with previ-
ous findings from studies of patients with varying severity 
of COPD (ICC ranging from 0.88 to 0.98),22,25–28 while ICC 
for inter-rater reliability was superior (lower limit [LL] 95% 
ICC: 0.94) to that reported by Labadessa et al28 (LL95% ICC: 
0.74). In contrast to previous studies, we did not find any 
systematic bias or clinical relevant learning effect when the 
test was conducted on the same day with 30 minutes of rest 
as recommended by the American Thoracic Society (ATS)/
European Respiratory Society (ERS).23,24,28,46 The results 
improved on average 7.9 m from T1 to T2. We cannot quan-
tify to which extent the systematic bias from T1 to T2 was 
related to a learning effect or the effect of different raters. 
However, we believe that an average improvement of that 
magnitude is of minor clinical significance if the purpose 
is to measure a treatment effect. The findings in our study 
group of patients with severe and very severe COPD contra-
dict previous findings of regular systematic bias in studies 
on heterogeneous groups of patients with varying severity 
of COPD (stage II–IV/moderate to very severe).21,22,24–26,28,46 
Without making the reservation that four of the previous 
studies used 30 minutes of rest between the two test trials and 
three studies used 24 hours and up to 7 days, their average 
intra-rater differences ranged from 16 to 37 m.21,22,25,26,28,34,46 
Previous studies on intra-rater reliability have shown learn-
ing improvements from the first to the second 6MWT in 
70%–82% of the patients while we found improvements in 
56% of the patients on T1 and in 62% of the patients from 
T1 to T2.22,25–27 Due to the concern that the learning effect 
exceeds the minimal important difference (MID) of 30 m 
documented in previous studies it is currently recommended 
by the ERS/ATS to complete at least two 6MWT when 
assessing patients with COPD.9,10 In our study, we found 
not only a proportion of 12% exceeding the MID of 30 m 
but also a counterpart of 10% decreasing by 30 m within the 
recommended minimum break of 30 minutes.
Although agreement parameters are preferable when 
measurement instruments are used for evaluation of changes 
over time,6–8 only one reliability study has reported the SEM 
Table 4 explorative results for 6MWD
Intra-rater test-day 1 (T1) Inter-rater (highest value T1 vs highest value T2)
Improvers  
(n)
Non-improvers  
(n)
Total  
count (n)
Improvers  
(n)
Non-improvers  
(n)
Total  
count (n)
$350 m 16 6 22a 14 10 24c
,350 m 12 16 28b 17 9 26d
Total count (n) 28 22 50 31 19 50
Notes: number of improvers and non-improvers with a BODe index38 cut off for the 6MWD. a18% (4/22) who walked $350 m improved their second 6MWD by $30 m 
and none showed a decrease by $30 m. b17% (2/28) who walked ,350 m improved their second 6MWD by $30 m while 18% (5/28) decreased their walking distance 
by $30 m. c8% (2/24) who walked $350 m improved their 6MWD by $30 m from T1 to T2 while 4% (1/24) decreased their walking distance by $30 m. d19% (5/26) who 
walked ,350 m improved their 6MWD by $30 m from T1 to T2 while 8% (2/26) decreased their walking distance with $30 m.
Abbreviations: 6MWD, six-minute walk distance; intra-rater, values obtained by the same rater on the same day; inter-rater, highest values obtained by two different raters 
on two separate test-days (T1 vs T2); BODE index, body mass index, airflow obstruction, dyspnea, and exercise capacity.
Table 5 explorative results for 30sec-sTs
Intra-rater test-day 1 (T1) Inter-rater (highest value T1 vs highest value T2)
Improver  
(n)
Non-improver  
(n)
Total  
count (n)
Improver  
(n)
Non-improver  
(n)
Total  
count (n)
.8 repetitions 8 27 35 16 20 36
#8 repetitions 4 11 15 5 9 14
Total count (n) 12 38 50 21 29 50
Note: number of improvers and non-improvers with a criterion-based cut off16,17,43 for the 30sec-sTs.
Abbreviations: 30sec-sTs, 30 second sit-to-stand test (repetitions); intra-rater, values obtained by the same rater on the same day; inter-rater, highest values obtained by 
two different raters on two separate test-days (T1 vs T2).
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and the smallest real difference (SRD) of 6MWD in patients 
with COPD.28 The time points for the measurements were 
similar to ours; however, our agreement parameters showed 
substantially less error variance (SEM-intra-rater: 15 m; 
SRD95%-intra-rater: 41 m; SEM-inter-rater: 21 m; SRD95%-
inter-rater: 57 m) compared to the findings in the study by 
Labadessa et al (SEM-intra-rater: 31 m; SRD95%-intra-rater: 
72 m; SEM-inter-rater: 37 m; SRD95%-inter-rater: 86 m).28 
Our intra-rater LOA from -45 to 47 m were approximately 
half the variance that has been stated in published studies 
with the lower limit ranging from -92 to -67 m and upper 
limits ranging from 103 to 120 m.25,27,28
Our findings regarding 6MWD do not confirm typical 
findings from previous studies. We can only speculate on 
the reasons for these findings. Our participants were patients 
with severe and very severe COPD (stage III–IV) who had 
limited reserve capacity. Thus, a potential learning effect 
may have been counteracted by fatigue or exhaustion when 
they performed two strenuous tests with 30 minutes pause 
between trials. In addition, the patients were not used to car-
rying out strenuous tests, and this may have influenced their 
motivation and performance. Ideally, the test and retest could 
have been performed on two separate days to allow for better 
restitution, but this would require two extra assessment visits. 
Since transportation and lack of energy were well-recognized 
barriers for participation, we anticipated that it would be 
difficult to persuade the patients to meet on two additional 
test-days. In support for this concern, 23 patients refused to 
participate in the study due to one extra assessment visit. 
Our results demonstrate that the magnitude of a potential 
learning effect is less dominant and prevalent in patients 
with severe and very severe COPD, especially in those with 
low initial walking capacity. The explorative analyses and 
Bland–Altman plot (Figure 2A) point toward a proportional 
difference indicating that those with low initial walking 
capacity, that is, a walking distance ,350 m, improved less 
in the second trial compared to those who walked longer dis-
tances. Thus, it could be hypothesized that a threshold cut off 
of ,350 m from the BODE index could be useful to discrimi-
nate between these two groups. However, this hypothesis 
needs confirmation in future research. The recommendation 
of two test trials with a break of minimum 30 minutes is based 
on results from studies among patients with heterogeneous 
disease severity, and it may not be as appropriate in a group 
of patients with severe and very severe COPD.
In our study, we also showed good reliability and an 
acceptable agreement regarding changes in oxygen satu-
ration (end SpO
2
), HR (end HR), and perceived dyspnea 
(end dyspnea) during the 6MWT. Our findings are in line 
with previous findings in groups with varying severity of 
COPD,25,27,28 and emphasize that these measurements can be 
used for evaluative purposes, for example, monitoring SpO
2
 
and HR during 6MWT.9,10
30sec-sTs
The main findings from the 30sec-STS were excellent reli-
ability and acceptable agreement. The average improvement 
of 0.6 repetitions from T1 to T2 was small and most likely 
of minor clinical significance if the purpose is to measure 
a treatment effect. Our findings on reliability and agree-
ment in patients with severe and very severe COPD were 
identical to the results reported in other patient groups with 
renal disease (ICC 0.93; SEM: 0.9; SRD: 2.6),47 type 2 
diabetes (ICC 0.92; SEM: 1.2; SRD: 3.3),33 hip osteoar-
thritis (ICC 0.88; SEM: 1.5; SRD: 3.5),31 acute medical 
illness (ICC 0.82; SEM: 1.32; SRD: 3.7),48 hip replace-
ment (ICC 0.88; SEM: 1.0; SRD: 2.8),30 cognitive impair-
ment (ICC 0.94; SEM: 0.9; SRD: 2.4),49 and hospitalized 
stroke (ICC 0.87; SEM: 1.0; SRD: 3.0).50
Our results showed that the measurement error in 30sec-
STS was small, indicating that the 30sec-STS would be 
sensitive to measuring relative small changes over time in 
patients with severe and very severe COPD. All our patients 
could complete the test, and in contrast to the 5STS the 30sec-
STS did not show a floor effect. Two studies have shown a 
significant association between results in the 30sec-STS and 
leg extension (r=0.48)15 and isokinetic quadriceps strength 
(r=0.78–0.81),17 which is crucial for the ability to perform 
chair rise. In addition, one study has shown that the test is 
valid for assessing muscle performance of the lower limbs 
in patients with COPD pre and post a COPD rehabilitation 
program.15 Thus, the 30sec-STS seems feasible for use in 
research and daily clinical practice. However, the MID and 
responsiveness of the test have yet to be investigated and 
established in patients with COPD.
strength and limitations and future 
perspectives
Our study has meticulously followed the GRRAS, includ-
ing reports on all relevant reproducibility domains for both 
intra- and inter-rater reproducibility, and a recommended 
sufficient sample of 50 patients. We used a rigorous stan-
dardized methodological assessment approach, that is, using 
the same walking course and avoiding influence of length 
and track layout on the walked distance, same chair height, 
tests were performed on the same time of the day, same rest 
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intervals, standardized instruction, and calibrated raters. 
However, there are some limitations. We cannot rule out 
that leg fatigue due to the many tests may have obliterated 
a possible learning effect. However, to limit the influence 
of fatigue we ensured that every patient felt rested and that 
oxygen saturation, HR, and perceived dyspnea were fully 
normalized to the resting level values before the retests were 
performed. Secondly, it was impossible to blind the raters 
to the results from the first test trial because they performed 
the second trial on the same test-day and this increases the 
risk of recall bias. The disclosed limitations to restrict the 
learning effect21,27,30,33,47 and a possible recall bias are similar 
to those known from existing publications.21–28 Regarding 
the inter-rater reproducibility, we were unable to estimate 
how large a proportion in the measurement difference from 
T1 and T2 relates to an actual learning effect, to the effect 
of different raters, or biological variation. Finally, variables 
such as anxiety, depression, and lung symptoms were not 
adjusted for.
Conclusion
In summary, the reproducibility of the 6MWT and 30sec-
STS was excellent in patients with severe and very severe 
COPD. In contrast to previous studies, we found no learn-
ing effects when following the standardized guidelines 
for testing. Compared with the results on T1, there was a 
significant average improvement of 7.9 m in 6MWD on 
T2, which was performed 7–10 days apart and assessed 
by different raters. We consider this difference minor and 
without clinical relevance, while the SEM of 20.5 m was 
acceptable and below the established MID for the 6MWT. 
The reproducibility of cardiorespiratory variables (satura-
tion, HR, and perceived dyspnea) was good and acceptable. 
Based on our findings, repeated 6MWT and 30sec-STS can 
be conducted by different raters in clinical practice, and 
one 6MWT and one 30sec-STS may be sufficient to assess 
patients with severe and very severe COPD. However, the 
responsiveness of 30sec-STS needs to be investigated in 
future studies.
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